Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Potential Benefits of AOD-9604 Although research is still ongoing, several potential benefits have been observed in studies
The following peptides from this catalog reconstitute with bacteriostatic water as the standard solvent: all GLP-1 compounds, Cagrilintide, AOD9604, MOTS-C, all CJC-1295 variants, Sermorelin, Tesamorelin, GHRP-6, Hexarelin, BPC-157, TB-500, BPC+TB Blend, KPV, Thymosin Alpha-1, Semax, Selank, Kisspeptin-10, PT-141, Epitalon, FOXO4-DRI, Snap-8, Mazdutide, and most other peptides in this catalog
Typical scheduling approaches for B Complex injections, from initial loading phases to personalized maintenance routines
Your Mobility Changes Are you more inactive because your balance has diminished dramatically
The peptide calculator can help with dosing math for both compounds, and the semaglutide dosage calculator handles the specific titration schedule for GLP-1 therapy
